<DOC>
	<DOCNO>NCT00190892</DOCNO>
	<brief_summary>This trial assess efficacious benefit safety issue associate concomitant use olanzapine carbamazepine treatment patient bipolar I disorder , manic mixed episode</brief_summary>
	<brief_title>Olanzapine Plus Carbamazepine Treatment Bipolar I Mania</brief_title>
	<detailed_description />
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Carbamazepine</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>1 . Have diagnosis bipolar disorder currently meet DSMIVTR criterion manic mixed episode 2 . Female patient must test negative serum pregnancy test time enrollment agree use medically accept contraception throughout study . 3 . Have YMRS score &gt; = 20 screening ( Visit 1 ) randomization ( Visit 2 ) visit . 1 . Have participate ( randomize ) clinical trial another investigational drug ( include olanzapine carbamazepine ) within 30 day prior Visit 1 2 . Have history agranulocytosis ( absolute neutrophil count &lt; 500/uL ) patient 's lifetime 3 . Have acute , serious unstable medical condition , include ( limited ) inadequately control diabetes ( HgbA1c &gt; 8 % ) ; severe hypertriglyceridemia ( fast triglyceride &gt; = 500 mg/dl ; hepatic insufficiency ( specifically degree jaundice ) ; recent cerebrovascular accident ; uncontrolled seizure disorder ; serious acute systemic infection immunologic disease : unstable cardiovascular disorder ( include ischemic heart disease ) ; renal , gastroenterologic , respiratory , endocrinologic , neurologic , hematologic disease ( specifically current absolute neutrophil count , &lt; 1500/uL ) 4 . Have substance dependence ( except nicotine caffeine ) , base DSMIVTR criterion , within 30 day prior study entry . 5 . Require concomitant treatment medication primarily central nervous system ( CNS ) activity , allow protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2007</verification_date>
</DOC>